Abstract
Introduction: During the height of the COVID-19 pandemic, breast cancer surgery advisory body guidance was issued in the UK prioritising ER negative or node positive patients for surgery. This necessitated the use of neoadjuvant endocrine treatment (NET) in deferring surgery for node negative, hormone receptor positive patients. Previous studies looking at the risk of conversion to node positive status during the surgical deferment time are few.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
